Logo image of MNKD

MANNKIND CORP (MNKD) Stock Fundamental Analysis

NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD

3.52  +0.09 (+2.62%)

After market: 3.4607 -0.06 (-1.68%)

Fundamental Rating

5

MNKD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. An interesting combination arises when we look at growth and value: MNKD is growing strongly while it also seems undervalued.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

MNKD had positive earnings in the past year.
In the past year MNKD had a positive cash flow from operations.
In the past 5 years MNKD reported 4 times negative net income.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

MNKD has a better Return On Assets (7.23%) than 92.74% of its industry peers.
The Return On Invested Capital of MNKD (22.19%) is better than 97.82% of its industry peers.
Industry RankSector Rank
ROA 7.23%
ROE N/A
ROIC 22.19%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

MNKD has a better Profit Margin (9.96%) than 93.10% of its industry peers.
MNKD's Operating Margin of 27.25% is amongst the best of the industry. MNKD outperforms 96.91% of its industry peers.
MNKD has a Gross Margin of 75.77%. This is amongst the best in the industry. MNKD outperforms 83.48% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 27.25%
PM (TTM) 9.96%
GM 75.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
The number of shares outstanding for MNKD has been increased compared to 1 year ago.
MNKD has more shares outstanding than it did 5 years ago.
MNKD has a better debt/assets ratio than last year.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

MNKD has an Altman-Z score of -7.68. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.68, MNKD is doing worse than 68.60% of the companies in the same industry.
The Debt to FCF ratio of MNKD is 13.30, which is on the high side as it means it would take MNKD, 13.30 years of fcf income to pay off all of its debts.
MNKD has a better Debt to FCF ratio (13.30) than 92.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 13.3
Altman-Z -7.68
ROIC/WACC2.04
WACC10.86%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

MNKD has a Current Ratio of 2.36. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.36, MNKD is doing worse than 71.69% of the companies in the same industry.
A Quick Ratio of 2.11 indicates that MNKD has no problem at all paying its short term obligations.
The Quick ratio of MNKD (2.11) is worse than 72.60% of its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2.11
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 125.00% over the past year.
The Revenue has grown by 43.50% in the past year. This is a very strong growth!
MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.29% yearly.
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)43.5%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%

3.2 Future

MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.66% yearly.
MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.58% yearly.
EPS Next Y131.63%
EPS Next 2Y80.31%
EPS Next 3Y59.12%
EPS Next 5Y43.66%
Revenue Next Year13.03%
Revenue Next 2Y14.1%
Revenue Next 3Y13.27%
Revenue Next 5Y13.58%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 39.11, the valuation of MNKD can be described as expensive.
Based on the Price/Earnings ratio, MNKD is valued cheaper than 91.65% of the companies in the same industry.
MNKD is valuated rather expensively when we compare the Price/Earnings ratio to 26.48, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 13.53 indicates a correct valuation of MNKD.
95.28% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.04, MNKD is valued rather cheaply.
Industry RankSector Rank
PE 39.11
Fwd PE 13.53
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

MNKD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MNKD is cheaper than 96.37% of the companies in the same industry.
92.56% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 49.04
EV/EBITDA 11.3
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

MNKD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 59.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y80.31%
EPS Next 3Y59.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANNKIND CORP

NASDAQ:MNKD (8/8/2025, 8:00:00 PM)

After market: 3.4607 -0.06 (-1.68%)

3.52

+0.09 (+2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05/amc
Inst Owners58.79%
Inst Owner Change0.07%
Ins Owners1.54%
Ins Owner Change4.2%
Market Cap1.07B
Analysts85.71
Price Target9.31 (164.49%)
Short Float %7.96%
Short Ratio8.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.59%
Min EPS beat(2)-18.3%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-77.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)-10.87%
EPS beat(8)3
Avg EPS beat(8)-19.02%
EPS beat(12)5
Avg EPS beat(12)-10.38%
EPS beat(16)6
Avg EPS beat(16)-8.65%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.38%
Max Revenue beat(2)0.9%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)3.43%
Revenue beat(12)9
Avg Revenue beat(12)6.54%
Revenue beat(16)12
Avg Revenue beat(16)6.34%
PT rev (1m)-3.22%
PT rev (3m)-11.28%
EPS NQ rev (1m)1.01%
EPS NQ rev (3m)12.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.65%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)-1.75%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)-0.54%
Valuation
Industry RankSector Rank
PE 39.11
Fwd PE 13.53
P/S 3.59
P/FCF 49.04
P/OCF 36.35
P/B N/A
P/tB N/A
EV/EBITDA 11.3
EPS(TTM)0.09
EY2.56%
EPS(NY)0.26
Fwd EY7.39%
FCF(TTM)0.07
FCFY2.04%
OCF(TTM)0.1
OCFY2.75%
SpS0.98
BVpS-0.19
TBVpS-0.22
PEG (NY)0.3
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.23%
ROE N/A
ROCE 27.56%
ROIC 22.19%
ROICexc 49.27%
ROICexgc 51.75%
OM 27.25%
PM (TTM) 9.96%
GM 75.77%
FCFM 7.33%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score7
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 13.3
Debt/EBITDA 3
Cap/Depr 93.83%
Cap/Sales 2.56%
Interest Coverage 5.56
Cash Conversion 33%
Profit Quality 73.61%
Current Ratio 2.36
Quick Ratio 2.11
Altman-Z -7.68
F-Score7
WACC10.86%
ROIC/WACC2.04
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y131.63%
EPS Next 2Y80.31%
EPS Next 3Y59.12%
EPS Next 5Y43.66%
Revenue 1Y (TTM)43.5%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
Revenue Next Year13.03%
Revenue Next 2Y14.1%
Revenue Next 3Y13.27%
Revenue Next 5Y13.58%
EBIT growth 1Y161.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y130.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.04%
OCF growth 3YN/A
OCF growth 5YN/A